Urgent Class Action Deadlines Loom for Synopsys and Integer Holdings Investors

2025-12-26 companies

New York, Thursday, 25 December 2025.
Synopsys shareholders face a critical December 30 deadline following a 36% stock decline, while Integer investors have until February to address allegations of misleading market positioning.

Imminent Deadlines for Securities Fraud Claims

Investors in Synopsys, Inc. (NASDAQ: SNPS) and Integer Holdings Corporation (NYSE: ITGR) are navigating a complex legal landscape this holiday season, with critical deadlines approaching for participation in class action lawsuits. The Rosen Law Firm has issued a stark reminder regarding the impending December 30, 2025, deadline for Synopsys shareholders to petition the court as lead plaintiffs [2]. This deadline is particularly pressing for investors who incurred losses exceeding $100,000, as legal counsel seeks to consolidate claims regarding alleged securities violations [2]. Meanwhile, a separate deadline of February 9, 2026, has been established for stakeholders in Integer Holdings, following allegations of misleading statements concerning the company’s competitive standing in the medical device market [1].

Synopsys: The AI Pivot and Design IP Struggles

The legal action against Synopsys stems from a dramatic market correction that occurred earlier this year, driven by disappointing financial disclosures. On September 10, 2025, the company’s share price plummeted by approximately 36%, falling from $604.37 to close at $387.78 [4]. This precipitous drop of 216.59 per share erased significant shareholder value overnight [4]. The catalyst for this decline was the release of the company’s third-quarter financial results on September 9, 2025, which revealed that its Design IP business had significantly underperformed expectations [5]. Specifically, the company reported quarterly revenue of $1.740 billion, missing its prior guidance range of $1.755 billion to $1.785 billion [5].

Integer Holdings: Electrophysiology Market Misrepresentations

While the Synopsys deadline is immediate, investors in Integer Holdings Corporation have until February 9, 2026, to seek lead plaintiff status [1]. This class action, covering the period between July 25, 2024, and October 22, 2025, focuses on allegations that the company overstated its competitive position within the electrophysiology (EP) manufacturing market [1]. The complaint alleges that Integer experienced a deterioration in sales for two specific EP devices, contradicting earlier positive statements about the company’s business operations and prospects [1]. The Rosen Law Firm notes that the company allegedly mischaracterized these EP devices as long-term growth drivers for its Cardio and Vascular segment, leading to investors suffering damages when the true state of affairs was revealed [1].

Summary of Investor Actions

As today is December 25, 2025, Synopsys investors have fewer than five days to act before the December 30 cutoff [2]. Legal firms including Rosen, Levi & Korsinsky, and Kahn Swick & Foti are actively consolidating claims, offering contingency fee representation for shareholders who suffered losses during the respective class periods [3][4][6]. Integer shareholders retain a longer window for action but are advised to review their portfolios regarding the July 2024 to October 2025 timeframe to determine eligibility for potential compensation [1].

Sources

Securities Litigation Class Action